Chi Van Dang, MD, PhD, and Elizabeth Barrett, MBA, are featured.
Chi Van Dang, MD, PhD, began his role as editor-in-chief of Cancer Research, a journal of the American Association for Cancer Research (AACR), on January 1. Dang is the scientific director of the Ludwig Institute for Cancer Research and a professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia, PA. He also serves on the Blue Ribbon Panel of the National Cancer Moonshot Initiative, is a fellow of the American Academy of Arts and Sciences, and chairs the NCI's Board of Scientific Advisors, and he previously served on the editorial board of the AACR's Cancer Discovery. Dang's lab established a link between MYC and energy metabolism in cancer cells, and his current research focuses on developing cancer therapies that exploit metabolic vulnerabilities of cancer cells.
Elizabeth Barrett, MBA, was named CEO of Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1. She succeeds Bruno Strigini, MBA, PharmD, who retired. Most recently, Barrett was the global president and general manager of Oncology at Pfizer, where she had worked since 2009. Previously, Barrett spent 3 years as vice president and general manager of Oncology at Cephalon and 13 years as vice president, Oncology Franchise, at Johnson & Johnson. She earned her business degree in marketing from Saint Joseph's University in Philadelphia, PA.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.